bs-23915R

[Primary Antibody]


MUC5B Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

| - DATASHEET - | | | 400-901-9800 |
|---|-----------------|---|-------------------------------------|
| Host: Rabl | oit Is a | otype: IgG | Applications: IHC-P (1:100-500) |
| Clonality: Polyclonal | | | IHC-F (1:100-500) IF (1:100-500) |
| GenelD: 7278 | 97 S | SWISS: Q9HC84 | |
| Target: MUC5B | | Reactivity: Rat (predicted: Human, Mouse) | |
| Immunogen: KLH conjugated synthetic peptide derived from human MUC5B: 1151-1250/5763. | | | |
| Purification: affinity purified by Protein A | | | Predicted MW.: 630 kDa |
| Concentration: 1mg/1ml | | | MW.: |
| Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. | | | Subcellular Location: Secreted |
| Background: Tumor Markers | | | |
| Mucins are high molecular mass, highly glycosylated macromolecules that are the major components of mucus secretions. MUC5B is a salivary mucin that is thought to contribute to the lubricating and viscoelastic properties of whole saliva. It is composed of 14.9% protein, 78.1% carbohydrate, and 7% sulfate (Troxler et al., 1995 [PubMed 8554565]).[supplied by OMIM] | | | |
| - VALIDATION I | | | |

VALIDATION IMAGES



Paraformaldehyde-fixed, paraffin embedded (Rat pancreas); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MUC5B) Polyclonal Antibody, Unconjugated (bs-23915R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.

- SELECTED CITATIONS -

- [IF=7.901] Zeng Z et al. Stimuli-Responsive Self-assembled Dendrimers for Oral Protein Delivery. J Control Release. 2019 Oct 28;315:206-213. ICC ;Human. 31672623
- [IF=7.727] Xue Wang. et al. Engineered liposomes targeting the gut-CNS Axis for comprehensive therapy of spinal cord injury. J Control Release. 2021 Mar;331:390 IF ;Human. 33485884